Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

Next Previous
Trial Profile

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pracinostat (Primary) ; Azacitidine; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms PRIMULA
  • Sponsors Helsinn

Most Recent Events

  • 10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
  • 01 May 2024 Results evaluating the efficacy/safety of pracinostat administered with AZA in adult patients with newly diagnosed AML ineligible to receive IC, published in the Leukemia Research
  • 03 Apr 2022 This trial has been completed in Hungary (Date of the global end of the trial : 02-Jul-2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top